Published in World J Gastroenterol on November 07, 2015
The Host Cell Transcription Factor EGR1 Is Induced by Bacteria through the EGFR-ERK1/2 Pathway. Front Cell Infect Microbiol (2017) 0.75
(18)F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging (2016) 0.75
FZD6, targeted by miR-21, represses gastric cancer cell proliferation and migration via activating non-canonical wnt pathway. Am J Transl Res (2016) 0.75
Ongoing surgical clinical trials on minimally invasive surgery for gastric cancer: Korea. Transl Gastroenterol Hepatol (2016) 0.75
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res (1992) 12.77
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem (1995) 12.61
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science (1998) 6.99
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA (2004) 6.96
An African origin for the intimate association between humans and Helicobacter pylori. Nature (2007) 6.91
Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem (1992) 6.54
A human model of gastric carcinogenesis. Cancer Res (1988) 6.52
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med (2007) 5.62
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 4.66
Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst (2000) 4.51
A model for gastric cancer epidemiology. Lancet (1975) 4.02
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther (2012) 3.81
Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev (2007) 3.43
Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology (2002) 3.39
Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol (2005) 3.25
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A (2008) 3.17
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
Long term follow up of patients treated for Helicobacter pylori infection. Gut (2005) 3.09
The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol (2006) 3.07
Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 3.02
Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science (2003) 3.00
Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer (2004) 2.88
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med (1998) 2.70
Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev (1997) 2.68
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut (1990) 2.58
Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol (2010) 2.57
Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol (2010) 2.56
Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter (2010) 2.50
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut (2012) 2.49
Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol (2013) 2.44
Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis (2010) 2.40
CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology (2006) 2.39
Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst (1991) 2.35
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther (2012) 2.25
Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology (2010) 2.17
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Comparative ultrastructural and functional studies of Helicobacter pylori and Helicobacter mustelae flagellin mutants: both flagellin subunits, FlaA and FlaB, are necessary for full motility in Helicobacter species. J Bacteriol (1995) 2.15
Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology (2011) 2.13
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol (2006) 2.09
Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res (2008) 2.08
The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut (2012) 2.05
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A (1995) 1.99
Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect (2000) 1.97
Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori. Nucleic Acids Res (1999) 1.97
Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology (2005) 1.91
Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology (2007) 1.91
A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology (2007) 1.88
Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst (2012) 1.88
Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet (1989) 1.84
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut (2013) 1.79
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Tertiary structure-function analysis reveals the pathogenic signaling potentiation mechanism of Helicobacter pylori oncogenic effector CagA. Cell Host Microbe (2012) 1.72
The gastric precancerous cascade. J Dig Dis (2012) 1.70
Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun (1999) 1.69
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut (2004) 1.68
Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut (2011) 1.67
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter (2002) 1.65
Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol (1998) 1.64
Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med (2008) 1.62
Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol (2003) 1.60
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology (2009) 1.53
Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology (2004) 1.52
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun (2001) 1.50
Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet (1993) 1.48
Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun (2000) 1.44
Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell Immunol (1999) 1.43
Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter (2012) 1.40
Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun (1998) 1.38
Helicobacter Pylori associated global gastric cancer burden. Front Biosci (Landmark Ed) (2009) 1.33
Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine (1998) 1.32
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology (2008) 1.26
Multiple peptidoglycan modification networks modulate Helicobacter pylori's cell shape, motility, and colonization potential. PLoS Pathog (2012) 1.26
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.24
Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J Immunol (2006) 1.23
Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer (2010) 1.22
The time to eradicate gastric cancer is now. Gut (2005) 1.22
In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol (2004) 1.22
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther (2011) 1.22
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2011) 1.21
vacA i-region subtyping. Gastroenterology (2008) 1.18
Purification and characterization of the urease enzymes of Helicobacter species from humans and animals. Infect Immun (1992) 1.17
Evidence that loss of sonic hedgehog is an indicator of Helicobater pylori-induced atrophic gastritis progressing to gastric cancer. Am J Gastroenterol (2005) 1.15